Clinical management of stage III non-small cell lung cancer in India: An expert consensus statement

被引:3
作者
Batra, Ullas [1 ,9 ]
Prabhash, Kumar [2 ]
Agarwal, Jai Prakash [3 ]
Darlong, Laleng [4 ]
Munshi, Anusheel [5 ]
Penumadu, Prashanth [6 ]
Thangakunam, Balamugesh [7 ]
Bansal, Abhishek [8 ]
机构
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, Delhi, India
[2] TATA Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[3] TATA Mem Hosp, Dept Radiat Oncol, Mumbai, Maharashtra, India
[4] Rajiv Gandhi Canc Inst & Res Ctr, Dept Oncosurg, Delhi, India
[5] Manipal Hosp, Dept Radiat Oncol, Delhi, India
[6] JIPMER, Dept Surg Oncol, Pondicherry, India
[7] Christian Med Coll & Hosp, Dept Pulmonol, Vellore, Tamil Nadu, India
[8] Rajiv Gandhi Canc Inst & Res Ctr, Dept Radiol, Delhi, India
[9] Rajiv Gandhi Canc Inst & Res Ctr, Sect 5, Delhi 110085, India
关键词
guidelines; immunotherapy; multidisciplinary team; PD-L1; inhibitors; unresectable NSCLC; VINORELBINE PLUS CISPLATIN; CONCURRENT CHEMORADIOTHERAPY; POSTOPERATIVE RADIOTHERAPY; INDUCTION CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; COMPUTED-TOMOGRAPHY; SURVIVAL OUTCOMES; BRAIN METASTASES; N2; DISEASE; PHASE-III;
D O I
10.1111/ajco.13938
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung cancer (NSCLC) is considered the most common type of lung cancer (>80% of all lung cancers); patients are often diagnosed at advanced stages of the disease. The management of NSCLC is considered challenging owing to variations in size, an extension of the tumors, involvement patterns, and classification. Although adequate literature and guidelines are available on the management of NSCLC in several countries, an Indian perspective on stage III NSCLC management is lacking. We used the modified Delphi approach to form consensus statements. A thorough literature search was done. The authors then convened and deliberated over published literature, available guidelines, and clinical judgment. Recommendation statements were formed for different clinical scenarios. These statements were sent as a form of survey to other oncologists, and their responses were recorded and mentioned. Evidence-based statements were formed for diagnosing and managing stage III NSCLC. These recommendation statements cover various aspects-surgical, radiation, and medical treatment in various clinical scenarios including adjuvant, neoadjuvant, and consolidation therapies.
引用
收藏
页码:606 / 617
页数:12
相关论文
共 74 条
  • [1] Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: lobe-specific or systematic?
    Adachi, Hiroyuki
    Maehara, Takamitsu
    Nakayama, Haruhiko
    Masuda, Munetaka
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2728 - 2731
  • [2] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [3] Chemoradiotherapy of locally advanced nonsmall cell lung cancer: state of the art and perspectives
    Antoni, Delphine
    Mornex, Francoise
    [J]. CURRENT OPINION IN ONCOLOGY, 2016, 28 (02) : 104 - 109
  • [4] Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
    Arriagada, Rodrigo
    Dunant, Ariane
    Pignon, Jean-Pierre
    Bergman, Bengt
    Chabowski, Mariusz
    Grunenwald, Dominique
    Kozlowski, Miroslaw
    Le Pechoux, Cecile
    Pirker, Robert
    Pinel, Maria-Izabel Sathler
    Tarayre, Michele
    Le Chevalier, Thierry
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 35 - 42
  • [5] Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
    Bezjak, Andrea
    Temin, Sarah
    Franklin, Gregg
    Giaccone, Giuseppe
    Govindan, Ramaswamy
    Johnson, Melissa L.
    Rimner, Andreas
    Schneider, Bryan J.
    Strawn, John
    Azzoli, Christopher G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2100 - U162
  • [6] Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach
    Bilfinger, Thomas V.
    Albano, Denise
    Perwaiz, Muhammed
    Keresztes, Roger
    Nemesure, Barbara
    [J]. CLINICAL LUNG CANCER, 2018, 19 (04) : 346 - 351
  • [7] Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypNO Stage III-N2 NSCLC after Induction Chemotherapy and Resection
    Billiet, Charlotte
    Peeters, Stephanie
    Decaluwe, Herbert
    Vansteenkiste, Johan
    Dooms, Christophe
    Deroose, Christophe M.
    Hendrikx, Marc
    De Leyn, Paul
    Bulens, Paul
    Karim, Rezaul
    Le Pechoux, Cecile
    Mebis, Jeroen
    De Ruysscher, Dirk
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 1940 - 1953
  • [8] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
    Bradley, Jeffrey D.
    Hu, Chen
    Komaki, Ritsuko R.
    Masters, Gregory A.
    Blumenschein, George R.
    Schild, Steven E.
    Bogart, Jeffrey A.
    Forster, Kenneth M.
    Magliocco, Anthony M.
    Kavadi, Vivek S.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Clifford G.
    Wynn, Raymond B.
    Koprowski, Christopher D.
    Olson, Michael R.
    Meng, Joanne
    Paulus, Rebecca
    Curran, Walter J., Jr.
    Choy, Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 706 - +
  • [9] Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
    Casal-Mourino, Ana
    Ruano-Ravina, Alberto
    Lorenzo-Gonzalez, Maria
    Rodriguez-Martinez, Angeles
    Giraldo-Osorio, Alexandra
    Varela-Lema, Leonor
    Pereiro-Brea, Tara
    Barros-Dios, Juan Miguel
    Valdes-Cuadrado, Luis
    Perez-Rios, Monica
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 506 - 518
  • [10] Clinicopathological Profile of Patients with Lung Carcinoma in a Tertiary Care Center
    Chandramouli, M. T.
    Hosmane, Giridhar Belur
    [J]. JOURNAL OF HEALTH AND ALLIED SCIENCES NU, 2021, 11 (01): : 18 - 20